Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range
Antagonism of the dopamine D3 receptor has been hypothesized to be beneficial for schizophrenia cognitive deficits, negative symptoms and extrapyramidal symptoms. However, recent animal and human studies have shown that most antipsychotics do not occupy D3 receptors in vivo, despite their considerab...
Saved in:
Main Authors: | Satoko Baba (Author), Takeshi Enomoto (Author), Tomoko Horisawa (Author), Takashi Hashimoto (Author), Michiko Ono (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2015-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
by: Shintaro Sakai, et al.
Published: (2021) -
Blonanserin overdose: A case report
by: Sandeep Kumar Goyal, et al.
Published: (2019) -
Blonanserin suppresses impulsive action in rats
by: Naoya Nishitani, et al.
Published: (2019) -
The range and nature of reproductive health research in the occupied Palestinian territory: a scoping review
by: Aisha Shalash, et al.
Published: (2019) -
Carbazole and tetrahydro-carboline derivatives as dopamine D3 receptor antagonists with the multiple antipsychotic-like properties
by: Zhongtang Li, et al.
Published: (2023)